A plaque assay is the gold standard method for measuring the concentration of infectious virus particles in a sample, and it works by letting individual viruses kill their way outward through a sheet of cells until the damage becomes visible as a clear hole, or “plaque,” that you can count with the naked eye. The technique dates back to bacteriophage research and was adapted for animal viruses in the 1950s by Renato Dulbecco and Marguerite Vogt.1PubMed Central. From plaques to pocks: carrying over bacteriophage assay techniques to the study of influenza and other animal viruses Despite the rise of molecular techniques like real-time PCR, plaque assays remain uniquely valuable because they measure only viruses that are actually capable of infecting and destroying cells, not just viral genetic material floating in solution.
Growing the Cell Monolayer
Every plaque assay starts with a healthy, uniform layer of host cells growing across the bottom of a culture dish or multi-well plate. These cells need to be susceptible to the virus you are testing, and they need to form a continuous sheet, called a confluent monolayer, so that any gap in the lawn at the end of the experiment represents genuine virus-caused destruction rather than a spot where cells never grew. The cell type matters enormously. For SARS-CoV-2, Vero cells are the workhorse. For dengue, Vero or BHK-21 cells are common. For bacteriophages, the “monolayer” is a bacterial lawn grown in soft agar.
Confluency is a practical concern, not just a textbook ideal. In most protocols, you want cells to be at or near full coverage on the day of infection. However, some cell lines are more forgiving. Researchers working with murine cytomegalovirus found that plaques formed normally on monolayers of M2-10B4 cells even when cultures were less than 50 percent confluent at the time of infection, as long as a reduced-viscosity overlay was also used.2PubMed Central. Resolving the titer of murine cytomegalovirus by plaque assay using the M2-10B4 cell line and a low viscosity overlay That flexibility is not universal, though. For most assays, starting with a well-formed monolayer prevents ambiguous results and uneven plaque formation.
Infection and Adsorption
Once the monolayer is ready, you add the virus. The sample is first diluted in a series of steps, each one reducing the concentration by a fixed factor, typically tenfold. This serial dilution is what makes counting possible. At the highest concentrations, virus will destroy the entire monolayer and you will see nothing useful. At the right dilution, individual virus particles land far enough apart that each one produces a discrete, countable plaque.
A small volume of diluted virus is placed on the cell monolayer and left to sit, usually with gentle rocking every 10 to 15 minutes to keep the liquid spread evenly. This phase is called adsorption, and the conditions during it, especially temperature and duration, directly affect how many viruses successfully attach to cells. For foot-and-mouth disease virus, for example, exposing virus to cell layers for 90 minutes at 37 °C or just 15 minutes at 43 °C before adding the overlay gave the highest plaque counts, while lower temperatures of 26 °C or 29 °C during adsorption failed to produce maximal numbers.3Virology. A plaque assay for foot-and-mouth disease virus and kinetics of virus reproduction
Not every virus follows the same rules. Colorado tick fever virus, for instance, showed markedly increased adsorption efficiency when serum proteins were added during this step and when adsorption was carried out at 25 °C rather than 37 °C.4PubMed Central. Plaque assay procedure for Colorado tick fever virus The takeaway is that adsorption conditions are not one-size-fits-all. If you are setting up a plaque assay for a virus that lacks an established protocol, optimizing the adsorption temperature, duration, and medium composition is one of the first things to get right.
Applying the Overlay
After adsorption, the liquid inoculum is removed and replaced with a semi-solid or viscous overlay medium. This is the step that makes a plaque assay a plaque assay rather than a simple infection experiment. The overlay prevents newly produced virus particles from drifting freely through the liquid and infecting distant cells. Instead, progeny viruses can only reach cells immediately next to the ones already infected, forcing the infection to spread outward in a tight circle from each original point of entry.5PubMed Central. Viral concentration determination through plaque assays: using traditional and novel overlay systems Each circle of dead or damaged cells becomes one plaque.
The classic overlay materials are agarose, agar, and carboxymethyl cellulose (CMC), all of which gel or thicken enough to restrict viral diffusion while still allowing nutrients to reach the cells. A newer option, microcrystalline cellulose sold under the brand name Avicel, has gained popularity because it is easier to handle and can produce especially large, well-defined plaques. In work with human coronavirus NL63, researchers compared agarose, CMC, and Avicel overlays and found that all three were suitable, but Avicel produced the largest and clearest plaques starting from the fourth day of infection.6PubMed Central. Plaque assay for human coronavirus NL63 using human colon carcinoma cells
The overlay is mixed with cell culture medium containing nutrients and serum so that the underlying cells stay alive throughout the incubation period. If the overlay solidifies too quickly or at too high a temperature, it can kill the cells before the virus has a chance to form plaques. If it is too liquid, viral particles drift and you get a smeared, uncountable mess instead of discrete spots.
Incubation, Fixation, and Staining
The plates go into an incubator, usually at 37 °C with a controlled CO₂ atmosphere, for anywhere from two to seven or more days depending on the virus. Slow-growing viruses need longer. Fast ones can produce visible plaques in a couple of days. During this time, the virus replicates through successive rounds of infection, and each plaque grows as more and more cells in the immediate area are destroyed.
Once the plaques have reached a countable size, the overlay is removed and the monolayer is fixed, typically with formaldehyde or methanol, to kill everything and preserve the pattern. The fixed cells are then stained with a dye, most commonly crystal violet, which binds to the proteins in surviving cells and turns them dark purple or blue. Dead cells wash away or fail to pick up the stain. Each plaque appears as a clear, unstained circle against a dark background of living cells. Some protocols use a neutral red vital stain added as part of a second overlay layer before fixation, which achieves a similar contrast by staining living cells red and leaving dead zones pale.7PubMed. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2
Counting Plaques and Calculating Titer
After staining, you count the plaques in each well. In practice, you look for wells where individual plaques are clearly separated and countable, often in the range of roughly 10 to 100 per well. Wells with too many plaques merge into an uncountable mess. Wells with zero or one plaque may be too dilute to be statistically reliable.
The basic calculation is straightforward: the virus titer, expressed as plaque-forming units per milliliter (PFU/mL), equals the number of plaques divided by the product of the dilution factor and the volume of virus inoculum added. If you count 45 plaques in a well that received 0.1 mL of a 1-in-a-million dilution, the titer is 45 divided by (10⁻⁶ × 0.1), giving 4.5 × 10⁸ PFU/mL.
More sophisticated statistical approaches use data from multiple dilutions simultaneously, applying weighted regression to improve precision and produce a confidence interval around the titer estimate rather than a single point value.8PubMed. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays These methods handle the inherent randomness of dilution and infection more gracefully than the simple formula, especially when plaque counts at adjacent dilutions do not scale perfectly.
What Plaque Morphology Tells You
Plaques are not all the same. Their size, shape, clarity, and edge definition can reveal important information about the virus producing them. Viral culture plaque morphology has been used as a marker for growth capability and cytopathic effect, and researchers have relied on plaque characteristics to assess viral fitness and to select pre-attenuation candidates for live viral vaccines.9Pediatric Research. Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children
Large, clear plaques generally indicate a virus that replicates quickly and spreads efficiently from cell to cell. Small plaques often suggest slower replication, less efficient spread, or a partially attenuated strain. This relationship has real predictive power. A study of vaccinia virus found that deletion of the F12L gene, which is required for actin-based cell-to-cell spread, produced very small plaques in culture and a virus that was severely attenuated in live mice. A dose 10,000 times higher than the amount of normal virus needed to cause severe disease still failed to produce illness.10PubMed Central. Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence That connection between small-plaque phenotype and reduced virulence is not universal across all viruses, but it appears frequently enough that plaque size is taken seriously as a marker.
Mixed plaque sizes on a single plate can indicate a genetically diverse viral population, sometimes called a quasispecies. If you see large and small plaques from the same stock, it could mean the sample contains variants with different replication characteristics. This observation can be a starting point for further investigation, such as picking and amplifying individual plaques to isolate genetically distinct clones.
The Double-Layer Agar Method for Bacteriophages
The plaque assay was invented for bacteriophages, and the phage version uses a slightly different setup than the animal virus version. Instead of growing adherent cells on a plate and then adding virus on top, phage assays mix the phage particles with their bacterial host in a thin layer of soft agar, which is then poured over a firmer base agar layer in a petri dish. The bacteria grow to form a dense lawn within the soft agar, and wherever a single phage particle has infected and lysed a bacterium, its progeny spread to neighboring bacteria. The result is the same: a visible clear zone in an otherwise opaque lawn.11PubMed. Enumeration of Bacteriophages by Plaque Assay
This double-layer agar (DLA) format has been refined extensively. When studying interactions between phages and antibiotics, researchers tested seven different modifications to the DLA procedure, varying where the antibiotic was placed and whether the base agar was included. They found that the overall number of plaques per plate depended mainly on the antibiotic used, but the specific DLA modification also influenced plaque count. The largest total number of plaques was obtained by adding the antibiotic to the bottom agar while keeping the top agar present.12PubMed Central. Double-Layer Agar (DLA) Modifications for the First Step of the Phage-Antibiotic Synergy (PAS) Identification These kinds of protocol details matter when you are trying to optimize the assay for specific research questions, such as evaluating phage-antibiotic synergy in therapeutic contexts.
Focus-Forming Assays for Non-Cytopathic Viruses
Not all viruses destroy cells visibly enough to produce clear plaques. Some replicate inside cells without causing obvious damage, or cause damage so slowly that waiting for a visible plaque would take impractically long. For these viruses, the focus-forming assay (FFA) offers an alternative that follows the same logic as a plaque assay but uses antibody staining to detect clusters of infected cells, called foci, rather than relying on cell death to create visible holes.
In a typical FFA, the infection and overlay steps are similar to a standard plaque assay. The difference comes at detection: instead of staining for dead cells, you fix the monolayer and then use an antibody that recognizes a viral protein, followed by a labeled secondary antibody that produces a visible or fluorescent signal. Each focus of infected cells lights up as a distinct spot that can be counted, giving a titer in focus-forming units (FFU/mL). This approach has been applied to dengue and Zika viruses, where it reveals critical aspects of virus-host interactions and allows quantification of viral loads.13PubMed Central. Combination of the Focus-Forming Assay and Digital Automated Imaging Analysis for the Detection of Dengue and Zika Viral Loads in Cultures and Acute Disease
The FFA is particularly useful when speed matters. A rapid FFA developed for adenovirus quantification used 96-well plates of HEK293A cells infected with serial dilutions. Forty-eight hours after infection, cells were fixed with methanol and stained with monoclonal antibodies followed by a fluorescent conjugate. An automated fluorescence microscopy system scanned the plates and counted positive cells.14PubMed. A rapid Focus-Forming Assay for quantification of infectious adenoviral vectors A related technique, the infrared fluorescent immunofocus assay, was developed for viruses like hepatitis A and measles that are non-cytopathic or only minimally so. Foci of infection were detected by scanning culture plates with an infrared imaging system after staining with an Alexa Fluor 680-conjugated antibody.15PubMed. Infrared fluorescent immunofocus assay (IR-FIFA) for the quantitation of non-cytopathic and minimally cytopathic viruses
Plaque Reduction Neutralization Tests
One of the most important applications of the plaque assay is not simply measuring how much virus is in a sample but measuring whether antibodies in a patient’s blood can block that virus. The plaque reduction neutralization test (PRNT) mixes a fixed amount of virus with serial dilutions of a serum sample before adding the mixture to the cell monolayer. If the serum contains neutralizing antibodies, those antibodies will bind to the virus and prevent it from infecting cells, reducing the number of plaques that form. The dilution at which plaque counts drop by 50 percent (PRNT₅₀) or 90 percent (PRNT₉₀) is reported as the neutralizing antibody titer.
This approach remains the reference standard for measuring functional immunity. A validated PRNT assay for SARS-CoV-2 demonstrated high accuracy with intra-assay precision of 100 percent for samples across different neutralizing antibody levels.16PubMed Central. Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2 Similarly, a dengue PRNT developed to support vaccine trials was validated with acceptable precision, accuracy, specificity, and a lower limit of quantitation of 10 for all four dengue serotypes.17PubMed Central. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development PRNTs are used routinely in vaccine clinical trials, seroprevalence surveys, and diagnostic confirmation when other antibody tests give ambiguous results.
Plaque Assays Versus Other Titration Methods
The plaque assay is not the only way to measure virus. Two common alternatives are the TCID₅₀ assay, which uses serial dilutions to find the dose that infects 50 percent of culture wells, and quantitative real-time PCR (qPCR), which measures the total amount of viral genetic material in a sample. Each tells you something different, and the numbers they produce are not interchangeable.
A comparison of all three methods using five SARS-CoV-2 variants illustrates the discrepancies. Plaque assay titers ranged from about 1.5 × 10⁶ to nearly 2 × 10⁷ PFU/mL, while TCID₅₀ values for the same isolates were consistently lower, differing by roughly half a log to nearly a full log depending on the variant. Meanwhile, real-time PCR titers were far higher still. The ratio of PFU to RNA copies ranged from about 1:3,000 for one variant up to 1:30,000 for another, meaning that for every infectious particle detected by plaque assay, there were thousands to tens of thousands of viral genome copies that PCR could detect.18PubMed Central. Comparison among plaque assay, tissue culture infectious dose and real-time RT-PCR for SARS-CoV-2 variants quantification
That gap exists because PCR detects all viral RNA, whether it belongs to intact, infectious virions, defective particles, or naked fragments. The plaque assay, by contrast, counts only viruses that can actually complete an infection cycle. This distinction is crucial in contexts like evaluating whether a patient is still contagious, assessing vaccine-induced neutralization, or determining whether an antiviral drug actually reduces the production of infectious virus rather than just knocking down RNA levels. Despite taking longer, plaque assays remain indispensable because that question of infectiousness is often the one that matters most. That said, the correlation between the methods is good enough that some labs use qPCR for rapid day-to-day work and calibrate their results against plaque assays periodically.19Microbiology and Immunology. Real‐time polymerase chain reaction as a rapid and efficient alternative to estimation of picornavirus titers by tissue culture infectious dose 50% or plaque forming units
Automated Plaque Counting
One of the long-standing frustrations with plaque assays is that counting plaques by eye is tedious, subjective, and slow. Two analysts looking at the same plate will sometimes disagree on borderline plaques, and fatigue over dozens or hundreds of plates introduces variability. Several groups have developed software and hardware solutions to address this.
Integrating fluorescent antibody staining with automated image-based counting has shown impressive results. One approach replaced traditional crystal violet staining with a fluorescence-labeled antibody and then used a plate-based cell imager for non-biased, non-subjective counting. The combination cut assay length by about 40 percent, from five days down to three, because the fluorescent signal was detectable before plaques grew large enough to see with the naked eye.20PubMed Central. Integration of Fluorescence Detection and Image-Based Automated Counting Increases Speed, Sensitivity, and Robustness of Plaque Assays
On the software side, standalone programs have been developed for labs that want automation without investing in specialized imaging hardware. PlaQuest, a Windows-based plaque-counting tool built for Chikungunya virus quantification, produced counts that strongly correlated with manual counts from four independent analysts and generated identical drug inhibition curves. It also worked across different assay formats, including both traditional cell-death-based and immunostain-based plaque assays for other RNA viruses.21Scientific Reports. Development of an automated plaque-counting program for the quantification of the Chikungunya virus Another tool, Viridot, is a free open-source R package for counting immunostained viral plaques and estimating neutralizing antibody titers. Testing showed that a single analyst using Viridot achieved plaque counts as similar to their own manual counts as to the manual count of a different analyst, meaning the software performed within the range of normal human variability.22PLOS Neglected Tropical Diseases. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus
Biosafety Considerations
Plaque assays involve handling live, replication-competent virus, which means biosafety practices are not an afterthought. The required containment level depends entirely on the pathogen. Common laboratory-adapted strains may be handled at biosafety level 2, but work with agents like SARS-CoV-2, Ebola, or Marburg virus requires BSL-3 or BSL-4 facilities. At the highest containment levels, the plaque assay itself has been used as a teaching example for proper technique in a BSL-4 environment, with specific emphasis on setting up and cleaning a Class II biosafety cabinet, waste management, and safe removal of inactivated samples from the containment zone.23PubMed Central. Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices
Even in lower-containment settings, the serial dilution and overlay steps generate aerosol risk from pipetting and plate manipulation. Using sealed containers during incubation, performing all open manipulations inside a biosafety cabinet, and decontaminating surfaces and liquid waste with appropriate disinfectants are standard practice. Fixation with formaldehyde or methanol at the end of the assay kills the virus and makes the plates safe to handle on the bench for staining and counting, but until that step, every plate is treated as containing infectious material.